Liebl, M. C. | Search bioRxiv

bioRxiv2026

HIPK2 regulates homology-directed DNA repair and PARP inhibitor sensitivity

Repair of DNA double-strand breaks (DSBs) by homologous recombination (HR) counteracts genome instability and carcinogenesis. Cancer cells frequently show defects in HR which can be therapeutically exploited by hypersensitivity to poly(ADP-ribose) polymerase inhibitor (PARPi) treatment. Here we identify an unforeseen function of HIPK2 in HR repair and PARPi sensitivity. HIPK2 accumulates at DSBs and associates with DSB repair factors at DNA damage foci. DSB recruitment of HIPK2 requires checkpoint kinase ATM activity. DNA repair pathway analysis revealed that HIPK2 depletion specifically impairs HR. Mechanistically, we found that HIPK2 binds BRCA1 and phosphorylates BRCA1 at Ser1191, a site that regulates damage-induced BRCA1 protein stability. Consistently, HIPK2 depletion or pharmacological inhibition of HIPK2 results in reduced BRCA1 protein levels, and sensitizes BRCA1-proficient cancer cells to IR damage and PARPi treatment. In sum, our results identify a role for HIPK2 in HR through regulating BRCA1 protein levels, and propose HIPK2 inhibition as a novel strategy to sensitize BRCA1-proficient cancer cells to PARPi treatment.

cell biology↗

bioRxiv2023

Novel hydroxamic acid derivative induces apoptosis and constrains autophagy in leukemic cells

IntroductionPosttranslational modification of proteins by reversible acetylation regulates key biological processes. Histone deacetylases (HDACs) catalyze protein deacetylation and are frequently dysregulated in tumors. This has spurred the development of HDAC inhibitors (HDACi). Such epigenetic drugs modulate protein acetylation, eliminate tumor cells, and are approved for the treatment of blood cancers. ObjectivesWe aimed to identify novel, nanomolar HDACi with increased potency over existing agents and selectivity for the cancer-relevant class I HDACs (HDAC1/-2/-3/-8). Moreover, we wanted to define how such drugs control the apoptosis-autophagy interplay. As test systems, we used human leukemic cells and embryonic kidney-derived cells. MethodsWe synthesized novel pyrimidine-hydroxamic acid HDACi (KH9/KH16/KH29) and performed in vitro activity assays and molecular modeling of their direct binding to HDACs. We analyzed how these HDACi affect leukemic cell fate, acetylation, and protein expression with flow cytometry and immunoblot. The publicly available DepMap database of CRISPR-Cas9 screenings was used to determine sensitivity factors across human leukemic cells. ResultsNovel HDACi show nanomolar activity against class I HDACs. These agents are superior to the clinically used hydroxamic acid HDACi vorinostat. Within the KH-series of compounds, KH16 (yanostat) is the most effective inhibitor of HDAC3 (IC50 = 6 nM) and the most potent inducer of apoptosis (IC50 = 110 nM; p<0.0001) in leukemic cells. KH16 though spares embryonic kidney-derived cells. Global data analyses of knockout screenings verify that HDAC3 is a dependency factor in human blood cancer cells of different lineages, independent of mutations in the tumor suppressor p53. KH16 alters pro- and anti-apoptotic protein expression, stalls cell cycle progression, and induces a caspase-dependent processing of the autophagy proteins ULK1 and p62. ConclusionThese data reveal that HDACs are required to stabilize autophagy proteins through a suppression of apoptosis in leukemic cells. HDAC3 appears as a valid anti-cancer target for pharmacological intervention. HighlightsO_LINovel HDACi with nanomolar activity against leukemic cells were synthesized. C_LIO_LIHDACi of the KH-series are superior to a clinical grade HDACi. C_LIO_LIHDACi of the KH-series modulate acetylation and phosphorylation of proteins. C_LIO_LIThe new HDACi KH16 regulates cell cycle arrest, apoptosis, and autophagy. C_LIO_LIApoptosis acts upstream of autophagy in KH16-treated cells. C_LI

pharmacology and toxicology↗